Skip to content

Neurocognitive and neuroimaging factors explaining differences in drug use in at-risk cannabis users.

Neurocognitive and neuroimaging factors explaining differences in drug use in at-risk cannabis users. - explanatory factors of differential drug use

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON32254
Enrollment
70
Registered
2008-07-18
Start date
2008-06-03
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

middelen afhankelijkheid (cannabis) cannabis addiction/ cannabis dependance

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male or Female, age 18-25 years, right handed;At-risk cannabis user group: 10-30 marijuana use episodes in the previous month and at least 240 marijuana use episodes in the past 2 years.;Control group 1: matched on gender and ethnicity to the cannabis user group with 1- 50 lifetime marijuana use episodes (Pope et al. 2001).;Control group 2: matched on gender and ethnicity to the cannabis user group with 0 lifetime marijuana use episodes (Pope et al. 2001).

Exclusion criteria

Exclusion criteria: Cannabis user group: seeking treatment or a history of treatment. Control group 1: cannabis use during the past year. (This will be verified by urinalysis.) Control group 2: cannabis use or ever used. The following exclusion criteria will be in effect for all groups: Score of more than 10 on the AUDIT screening questionnaire for alcohol related problems (Saunders et al. 1993). Smoking more than one pack of tobacco cigarettes per day. Current use of prescription or illicit psychoactive drugs other than marijuana. More than 100 lifetime uses of any non-cannabinoid class of drug of abuse (Kouri et al. 1999; Pope et al. 2001). Trying to stop alcohol or tobacco use. Unstable medical illness (e.g., hypertension, diabetes, myocardial infarction). Current Axis I psychiatric disorder.

Design outcomes

Primary

MeasureTime frame
Personality characteristics, behavioural scores, brainactivity, and brain connectivity.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)